TOR1AIP1 and congenital myasthenic syndrome: With regard to therapeutics, three patients with TOR1AIP1-related CMS benefited from treatment with pyridostigmine [4,7], which stresses the need for early identification of these patients with neuromuscular transmission dysfunction.